Liquidation of a large block of stock

In the financial engineering literature, stock-selling rules are mainly concerned with liquidation of the security within a short period of time. This is practically feasible only when a relative smaller number of shares of a stock is involved. Selling a large position in a market place normally depresses the market if sold in a short period of time, which would result in poor filling prices. In this paper, we consider the liquidation strategy for selling a large block of stock by selling much smaller number of shares over a longer period of time. In particular, we treat the selling rule problem by using a fluid model in the sense that the number of shares are treated as fluid (continuous) and the corresponding liquidation is dictated by the rate of selling over time. The objective is to maximize the expected overall return. The underlying problem may be formulated as a stochastic control problem with state constraints. Method of constrained viscosity solution is used to characterize the dynamics governing the optimal reward function and the associated boundary conditions. Numerical examples are reported to illustrate the results.     

Libéralisation financière,développement financier et croissance économique: Nouvelle évidence empirique

Résumé: La relation entre le développement financier et la croissance économique a suscité beaucoup d’attention ces dernières années dans la littérature économique. Dans ce papier, nous avons présenté, en premier lieu, l’effet du développement bancaire sur la croissance économique à travers une validation empirique en données de panel d’un modèle à effets aléatoires de 52 pays de 1980 à 2005, et en second lieu, nous avons essayé d’explorer les liens qui peuvent exister entre le développement financier au sens large (bancaire et boursier) et la croissance économique à travers une analyse en coupe transversale pour 42 pays durant la période 1988–2002. Les principaux résultats retenus de ce travail montrent que le niveau du développement financier au sens large peut être un facteur important pour la croissance économique. Toutefois, force est de signaler que cette contribution est conditionnée par la réunion de certaines conditions.     

Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a major health problem in Egypt with a high impact on morbidity, mortality, and healthcare resources. This study evaluated the budget impact and the long-term consequences of dapagliflozin versus other conventional medications, as monotherapy, from both the societal and health insurance perspectives in Egypt.

Methods: A static budget impact model was developed to estimate the financial consequences of adopting dapagliflozin on the healthcare payer budget. We measured the direct medical costs of dapagliflozin (new scenario) as monotherapy, compared to metformin, insulin, sulphonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinedione, and repaglinide (old scenarios) over a time horizon of 3 years. Myocardial infarction (MI), ischemic stroke, hospitalization for heart failure (HHF), and initiation of renal replacement therapy (RRT) rates were captured from DECLARE TIMI 58 trial. One-way sensitivity analyses were conducted.

Results: The budget impact model estimated 2,053,908 patients eligible for treatment with dapagliflozin from a societal perspective and 1,207,698 patients from the health insurance (HI) perspective. The new scenario allows for an initial savings of EGP121 million in the first year, which increased to EGP243 and EGP365 million in the second and third years, respectively. The total cumulative savings from a societal perspective were estimated at EGP731 million. Dapagliflozin allows for savings of EGP71, EGP143, and EGP215 million in the first, second and third years respectively, from the HI perspective, with total cumulative savings of EGP430 million over the 3 years.

Conclusion: Treating T2DM patients using dapagliflozin instead of conventional medications, maximizes patients’ benefits and decreases total costs due to drug cost offsets from fewer cardiovascular and renal events. The adoption of dapagliflozin is a budget-saving treatment option, resulting in substantial population-level health gains due to reduced event rate and cost savings from the perspective of the national healthcare system.     

LIQUIDATION OF A LARGE BLOCK OF STOCK WITH REGIME SWITCHING

In the literature, stock‐selling rules are mainly concerned with liquidation of the security within a short period of time. In practice, this is feasible only when a relatively smaller number of shares of a stock is involved. Selling a large position in a market place normally depresses the market if sold in a short period of time, which would result in poor filling prices. Comparing to the existing results in the literature, this work has two distinct features. First, the underlying stock price is modeled using a geometric Brownian motion formulation with regime switching in which the jump rate depends on the selling intensity. A larger selling intensity makes the regime more likely to change from a higher return mode to a lower one or forces the return mode to stay in the lower one longer. Secondly, we consider the liquidation strategy for selling a large block of stock by selling much smaller number of shares over a longer period of time. By using a fluid model, in which the number of shares is treated as fluid (continuous), we treat the selling rule problem where the corresponding liquidation is dictated by the rate of selling over time. Our objective is to maximize the expected overall return. Thus it may be formulated as a stochastic control problem with state constraints. Method viscosity solution is used to characterize the dynamics governing the optimal reward function and the associated boundary conditions. Numerical examples are reported to illustrate the results.